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Background: Interleukin-4(IL-4) is a critical inflammatory cytokine and has been involved in pathogenesis of cancer.
To date, several studies have investigated the association between IL-4 intron 3 variable number of tandem repeats
(VNTR) polymorphism and cancer risk in humans; however, the results remain controversial. We performed this
meta-analysis to find a more conclusive association between this polymorphism and cancer risk.
Methods: Eight eligible case–control studies were identified through searching electronic databases, including
1583 cases and 1638 controls. Odds ratio (OR) and corresponding 95% confidence interval (CI) were used to
estimate the strength of the association.
Results: The results of overall analyses indicated that the variant RP2 allele was associated with a decreased cancer
risk compared with the RP1 allele (RP2/RP2 vs. RP1/RP1, OR = 0.64, 95% CI = 0.44-0.94; RP2/RP2 vs. RP1/RP1 + RP1/
RP2, OR = 0.75, 95% CI = 0.60-0.92; RP2 vs. RP1, OR = 0.72, 95% CI = 0.56-0.92). In subgroup analyses stratified by
ethnicity, there was evidence in the Asian population for an association between this polymorphism and cancer risk
(RP2/RP2 vs. RP1/RP1 + RP1/RP2, OR = 0.79, 95% CI = 0.63-0.99; RP2 vs. RP1, OR = 0.77, 95% CI = 0.61-0.97).
Conclusions: IL-4 intron 3 VNTR polymorphism could influence the risk of human cancer. Due to the limitations of
this meta-analysis, further well-designed and functional researches should be performed to validate our results.
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Cancer is currently a major health burden in the world
which results from complicated interactions between
genetic and environmental factors [1,2]. Epidemiological
studies have revealed that chronic inflammation could
pose a risk factor for several cancers [3]. Moreover,
inflammation has been linked to the pathogenesis of
tumors in up to 15% of human cancers [4]. Cytokines
are important inflammatory mediators and there is evi-
dence that human predisposition to cancer could be in-
fluenced by polymorphisms located in genes encoding
cytokines and their receptors [5].
Interleukin-4(IL-4), produced by activated Th2 type
CD4+ T cells, represents a key differentiation cytokine
that induces development of Th2 subset of lymphocytes,
which is responsible for surveillance and clearance of* Correspondence: zhangsuzhan@hotmail.com
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unless otherwise stated.tumor cells by activation of granulocytes and eosi-
nophils, as well as inhibition of angiogenesis [6,7]. More-
over, Th2 subset is involved in antagonizing IFN-γ
function, B cell switching to IgE production, inhibiting
macrophage activation and some studies have revealed
its anti-tumor activity on several cancers such as colon,
breast and renal carcinoma [8,9]. However, IL-4 plays a
bilateral role in the control of tumor growth. It has been
reported that IL-4 could promote the initiation, progres-
sion and spread of head and neck squamous carcinoma
[10-13]. Liang et al. [14] have found that there was a sig-
nificantly higher level of IL-4 mRNA in patients with
gastric cancer in stage III and IV than that in stage I and
II. In addition, IL-4 also disturbs anti-tumor immunity
by down-regulating the expression of Th1 cytokines
[10,15] and impairing the CD8+ T cell immune response
in the tumor microenvironment [6,11].
The gene encoding IL-4 is located on chromosome
5q31.1 [16]. A rapidly growing number of epidemiologic
studies have been conducted to investigate the effect oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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important polymorphism is located in the intron 3 of
IL-4 gene and is composed of a 70-bp sequence of vari-
able number of tandem repeats (VNTR) [17,18]. It has
been proved that the IL-4 intron 3 polymorphism might
influence the production of IL-4, with the RP1 (two
70-bp repeats) allele enhancing IL-4 expression com-
pared with RP2 (three 70-bp repeats) allele [18,19].
To date, several case–control studies have been carried
out to explore the linkage between IL-4 intron 3 VNTR
polymorphism and the risk of several human cancers.
However, results from different articles remain contro-
versial. We performed this meta-analysis based on the
published studies to make a more conclusive evaluation




Relevant articles indexed in PubMed and Cochrane
Library (from inception to July 30, 2014) were indepen-
dently searched by two authors, using the key words as
follows: (“interleukin-4” or “interleukin 4” or “IL-4” or
“IL 4”) and (“tumor” or “cancer” or “carcinoma” or “neo-
plasm” or “malignancy”) and (“polymorphism” or “poly-
morphisms” or “SNP” or “variant” or “variation”). The
retrieved results were filtered to English language papers.
An additional manual search was performed among the
references of relevant articles and related articles in
PubMed.
Study identification
All the retrieved articles were reviewed by two authors
independently to select studies for inclusion. As for
studies with overlapping data reported by the same in-
vestigators, the articles with the most complete data
were eligible. Studies included in this meta-analysis
should meet the following predetermined criteria: 1)
case–control design, 2) evaluation of the IL-4 intron 3
VNTR polymorphism and cancer risk, 3) effective esti-
mation of odd ratio (OR) with 95% confidence interval
(CI), or enough data to allow calculation of these two
statistics. The major criteria for exclusion were: 1) not
relevant to IL-4 polymorphism and cancer risk, 2) not
with a case–control design (eg, animal studies, reviews,
case reports, letters, and editorials), 3) study on inherited
cancers, 4) duplicate data.
Data extraction
Two authors checked each included article independently
to extract the necessary data. The following information
were collected: first author’s last name, publication year,
ethnicity of the study population, country where the
study conduct, sample size, source of the control groups(hospital- or population-based), the distribution of variant
genotypes of both cases and controls.
Statistical analysis
Pooled analysis was performed to estimate the strength
of the association between IL-4 polymorphism and can-
cer risk using the odds ratio (OR) with 95% confidence
interval (CI). The pooled ORs were calculated by a co-
dominant model (RP2/RP2 vs. RP1/RP1, RP1/RP2 vs.
RP1/RP1), a dominant model (RP2/RP2 + RP1/RP2 vs.
RP1/RP1), a recessive model (RP2/RP2 vs. RP1/RP1 +
RP1/RP2), and an allelic model (RP2 vs. RP1). The
values of the pooled ORs were tested by Z-test [20].
Hardy-Weinberg equilibrium (HWE) was estimated using
goodness-of-fit test based on the chi-square test in the
control groups of each study [21].
Heterogeneity among the included studies was evalu-
ated using chi-square based on Q-test and I2 statistic
[22]. Pooled ORs were calculated using a fixed (Mantel-
Haenszel method [23]) or random (DerSimonian-Laird
method [24]) effective model according to the absence
(I2 < 50%) or presence (I2 > 50%) of heterogeneity. Sen-
sitivity analyses were conducted by removing one study
each time to assess the stability of the results. The po-
tential publication bias of the included studies was eva-
luated by Begg’s funnel plots graphically and Egger’s
linear regression test [25].
All the tests were two sides and it is deemed to be sta-
tistically significant when P < 0.05. All the statistical ana-
lyses were carried out with Stata/SE software version
12.0 (StataCorp LP, College Station, TX, USA).
Results
Literature search and characteristics of eligible studies
Our search in electronic databases identified 444 records.
Four hundred and one records were excluded after
reviewing titles and abstracts and we gained 43 useful
studies. After full-text reviewing, we excluded 35 studies
and listed the reasons for their exclusion in Figure 1.
There were 8 studies [26-33] suitable for this meta-
analysis finally, involving a total of 1583 cases and 1638
controls. Seven of the included studies were conducted
on an Asian population and the rest one was on a
Caucasian population. Characteristics of eligible studies
were summarized in Table 1.
Quantitative synthesis
The main results of this meta-analysis were presented in
Table 2. In the overall analyses, there was an association
between the variant genotypes and cancer risk in several
genetic models. Significantly decreased cancer risk was ob-
served in the co-dominant model (RP2/RP2 vs. RP1/RP1,
OR = 0.64, 95% CI = 0.44-0.94), recessive model (RP2/RP2
vs. RP1/RP1 + RP1/RP2, OR = 0.75, 95% CI = 0.60-0.92),
Figure 1 Flow diagram of the study identification process.
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0.56-0.92) (Figure 2). In subgroup analyses stratified
by ethnicity, there was evidence in the Asian popu-
lation for an association between this polymorphism
and cancer risk (RP2/RP2 vs. RP1/RP1 + RP1/RP2,
OR = 0.79, 95% CI = 0.63-0.99; RP2 vs. RP1, OR = 0.77,
95% CI = 0.61-0.97). According to a specific cancer
type, declined risk among studies of bladder cancer
was found in all genetic models.Table 1 Characteristics of eligible studies in the meta-analysi
ID First
author
Year Country Ethnicity S
c
1 Tsai FJ 2005 China Asian P
2 Tsai MH 2005 China Asian H
3 Lai KC 2005 China Asian N
4 Kesarwani P 2008 India Asian H
5 Konwar R 2009 India Asian H
6 Shekari M 2011 India Asian H
7 Yang CM 2014 China Asian H
8 Bozdogan T 2014 Turkey Caucasian H
PB population-based controls; HB hospital-based controls; HWE Hardy-Weinberg equIn addition, we omitted 1 study in which the control
group was not in agreement with HWE [30] and re-
peated the meta-analysis. The result was consist with
the overall analyses (RP1/RP2 vs. RP1/RP1, OR = 0.74,
95% CI = 0.49-1.13; RP2/RP2 vs. RP1/RP1, OR = 0.62,
95% CI = 0.41-0.95; RP2/RP2 + RP1/RP2 vs. RP1/RP1,
OR = 0.71, 95% CI = 0.46-1.09; RP2/RP2 vs. RP1/RP1 +
RP1/RP2, OR = 0.78, 95% CI = 0.61-0.98; RP2 vs. RP1,
OR = 0.71, 95% CI = 0.53-0.94).s
ource of
ontrols
Cancer type Sample size HWE
Case Control
B Bladder cancer 138 105 0.720
B Oral cancer 130 105 0.720
ot shown Gastric cancer 123 103 0.961
B Prostate cancer 491 501 0.859
B Breast cancer 100 200 0.001
B Cervical cancer 200 200 0.406
B OPSCC 592 623 0.146
B Bladder cancer 100 102 0.199
ilibrium; OPSCC oral and pharyngeal squamous cell carcinoma.
Table 2 Pooled analysis of association between IL-4 intron 3 VNTR polymorphism and cancer risk
Variables Study N Sample size Test of association Test of heterogeneity Model Egger's test
(P-value)Case Control OR(95% CI) P-value Ph I
2(%)
RP1/RP2 vs RP1/RP1 Overall 8 1198 1142 0.79(0.54-1.15) 0.216 0.020 58.0 R 0.631
Ethnicity Asian 7 1160 1119 0.82(0.57-1.17) 0.264 0.033 56.3 R 0.950
Cancer type Bladder 2 175 123 0.26(0.14-0.49) 0.000 0.297 7.9 F -
RP2/RP2 vs RP1/RP1 Overall 8 1112 1131 0.64(0.44-0.94) 0.021 0.158 33.9 F 0.051
Ethnicity Asian 7 1041 1052 0.75(0.51-1.10) 0.139 0.385 5.5 F 0.225
Cancer type Bladder 2 191 151 0.07(0.01-0.38) 0.002 0.572 0.0 F -
RP2/RP2+RP1/RP2 vs RP1/RP1 Overall 8 1583 1638 0.73(0.49-1.07) 0.102 0.009 62.4 R 0.462
Ethnicity Asian 7 1483 1536 0.76(0.53-1.08) 0.126 0.022 59.5 R 0.860
Cancer type Bladder 2 238 207 0.23(0.13-0.43) 0.000 0.213 35.5 F -
RP2/RP2 vs RP1/RP1+RP1/RP2 Overall 8 1583 1638 0.75(0.60-0.92) 0.007 0.335 12.2 F 0.055
Ethnicity Asian 7 1483 1536 0.79(0.63-0.99) 0.045 0.475 0.0 F 0.043
Cancer type Bladder 2 238 207 0.42(0.21-0.85) 0.044 0.302 6.3 F -
RP2 vs RP1 Overall 8 - - 0.72(0.56-0.92) 0.008 0.002 68.8 R 0.066
Ethnicity Asian 7 - - 0.77(0.61-0.97) 0.027 0.011 64.0 R 0.159
Cancer type Bladder 2 - - 0.36(0.24-0.53) 0.000 0.438 0.0 F -
Note: N number of studies, Ph P-value of Q-test for heterogeneity, R random-effects model, F fixed-effects model, Bold values indicate significant results.
Figure 2 Forest plot for the overall association between IL-4 intron 3 VNTR polymorphism and cancer risk for an allelic model (RP2
versus RP1).
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There was significant heterogeneity in the overall ana-
lyses for the comparison of the allelic model (RP2 vs.
RP1: P = 0.002 and I2 = 68.8% for heterogeneity). Sensi-
tivity analyses were carried out to explore the origin of
heterogeneity. Two studies [26,33] were under suspicion
and the heterogeneity was remarkably decreased after
omitting these two articles (RP2 vs. RP1: OR = 0.87, 95%
CI = 0.76-0.99, P = 0.546 and I2 = 0.00% for heterogeneity).
Moreover, the pooled ORs in all genetic models were not
altered qualitatively when any single study was removed,
which indicated the results of the present meta-analysis
were relatively stable and credible (Figure 3).
Publication bias
The publication bias of eligible literatures was assessed
by Begg’s funnel plots graphically and Egger’s test statis-
tically. The shapes of funnel plots in all models did not
show any evidence of an obvious asymmetry (Figure 4).
Meanwhile, the Egger’s test indicated no publication bias
either (RP1/RP2 vs. RP1/RP1: P = 0.631, RP2/RP2 vs.
RP1/RP1: P = 0.051, RP2/RP2+ RP1/RP2 vs. RP1/RP1:
P = 0.462, RP2/RP2 vs. RP1/RP1 + RP1/RP2: P = 0.055,
RP2 vs. RP1: P = 0.066).
Discussion
Cancer is a heterogeneous disease resulting from genetics,
environmental factors, and their interactions, the clinical
outcome of which is difficult to predict [34-36]. Inflam-
mation has been associated with variant malignancies.Figure 3 Sensitivity analysis for the overall association between IL-4 i
(RP2 versus RP1).Elevated levels of inflammatory cytokines have been
linked to inflammatory exacerbation. As a critical anti-
inflammatory cytokine, IL-4 has implicated in the pa-
thogenesis of various cancers. Elevated plasma levels of
IL-4 were correlated with risk of acute myeloid leukemia,
melanoma, head and neck squamous cell carcinoma, non-
small-cell lung cancer, prostate, colon, breast, renal cell
cancer [37-40], and were associated with poor prognosis
in non-Hodgkin lymphoma [41]. More specifically, several
polymorphisms of the gene encoding IL-4 have been
proved to be risk factors for cancer [33,42-45]. Besides
the most common polymorphisms, −590C > T(rs2243250)
and -33 T > C(rs2070874), the intron 3 VNTR polymor-
phism also plays an important role in alteration of IL-4
production.
To our knowledge, Li et al. performed a meta-analysis
about the association of IL-4 intron 3 VNTR poly-
morphism and cancer risk [46]. Their results showed
that there was no association between this polymor-
phism and cancer risk. However, some concerns were
related to this meta-analysis. First, the sample size was
relatively small, involving 791 cases and 772 controls
from 5 case–control studies. Second, there was signifi-
cant heterogeneity and the origin of heterogeneity was
not well explored. In addition, several important studies
about the association of IL-4 intron 3 VNTR poly-
morphism and cancer risk have been published recently.
The present meta-analysis, including 1583 cases and
1638 controls from 8 case–control studies, comprehen-
sively assessed the association between IL-4 intron 3 VNTRntron 3 VNTR polymorphism and cancer risk for an allelic model
Figure 4 Begg’s funnel plot for the overall association between IL-4 intron 3 VNTR polymorphism and cancer risk for an allelic model
(RP2 versus RP1).
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sociation between IL-4 intron 3 VNTR polymorphism and
cancer risk. Our results indicated the RP1 allele might be a
risk factor for malignancies. The results were robust be-
cause the pooled ORs did not alter in sensitivity analyses.
Stratified analyses suggested that the association was mainly
in Asian populations and in bladder cancer. Since there was
significant heterogeneity in several genetic models, two
studies were founded out by sensitivity analyses. We re-
checked these 2 studies and found that 1 study [26] was the
only population-based design in the 8 included studies and
the other one [33] was the only one that conducted on a
Caucasian population. In addition, we pooled the data from
studies on diverse cancer types, which might contribute to
some extent of the heterogeneity. Different cancer types
might give rise to different host responses, and the inter-
actions between different environmental factors and host
might also influence the susceptibility to different cancer
types. Because of the limited study number, we could not
perform a meta-regression analysis to estimate the extent
of heterogeneity from different cancer types.
Some limitations of our meta-analysis should be pointed
out. First, the pooled outcomes were calculated based on
unadjusted estimates, which limited a more precise evalu-
ation on adjusted estimates by several important factors
like age, sex, lifestyle and etc. Only one study reported that
IL-4 intron 3 VNTR polymorphism was associated with
oral and pharyngeal carcinoma risk, which interacted with
alcohol drinking [32]. Thus, lacking of these original infor-
mation limited supplementary assessment of the potential
interactions because gene-gene, gene-environment inter-
actions and other polymorphisms of the same gene might
influence cancer predisposition. Second, most of the
studies included in the present meta-analysis onlyfocused on the relationship between IL-4 intron 3
VNTR polymorphism and cancer risk, which made it
hard to assess the effects of IL-4 haplotypes composed
of different IL-4 polymorphisms on carcinogenesis.
There was evidence that IL-4 -590C > T(rs2243250),
−33 T > C(rs2070874) polymorphisms were associated
with cancer risk [42,43,45]. Thus, the status of other IL-4
polymorphisms might cover up the impact of intron 3
VNTR polymorphism on carcinogenesis. Third, limited
study number restricted us to perform additional sub-
group analyses. Forth, although there was no publication
bias statistically, the potential publication bias might exist
because some studies with negative results were not pub-
lished. Moreover, there was only one study conducted on
the Caucasian population and no study on the African
population in this meta-analysis.
Despite these limitations, advantages in our meta-analysis
should be also acknowledged. First, the statistical power
was definitely increased by pooling a substantial number of
cases and controls. Second, all the eligible studies met the
inclusion and exclusion criteria strictly and completely.
Third, no publication bias was detected through Begg’s fun-
nel plots and Egger’s test, which indicated that the pooled
results should be unbiased.
In conclusion, the results of this meta-analysis were sta-
tistically credible. The relationship between IL-4 intron 3
VNTR polymorphism and cancer risk was assessed and this
polymorphism was associated with cancer risk, mainly in
Asians. To draw a more precise conclusion, further studies
should be carried out with more detailed individual infor-
mation, concerning the effects of other polymorphisms and
haplotypes, enrolling larger sample size of cases and well-
matched controls, especially in Caucasians and Africans, to
validate the role of IL-4 polymorphism in carcinogenesis.
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